Endocrine Abstracts

Introduction: Alemtuzumab is a monoclonal antibody targeting the CD52 glycoprotein, which is expressed by most mature leucocytes. In early relapsing-remitting multiple sclerosis (MS) alentuzumab effectively decreases relapse rate and disability progression. However, nearly 50% of the pacients treated with alentuzumab develop secondary autoimmune disorders, being Graves’ disease the most common. The development of thyroid eye disease is unusual.Aims ...